SIK2 and ovarian carcinoma: The potential of our new SIK2 inhibitor, MRIA9, was also demonstrated in 3D- spheroid assays of two ovarian cancer cell lines, SKOV-3 and OVCAR-3, and in primary ovarian cancer cells originating from different patients.